Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Humanigen, Inc.

Humanigen Reports Second Quarter 2022 Financial Results
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
NIH/NIAID Locks ACTIV-5/BET-B Database
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Participation and Presentation at Multiple Conferences in June
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Reports First Quarter 2022 Financial Results
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Participation and Presentation at Multiple Conferences in May
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen to Present and Participate at Multiple Investor Events in March
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen to Present at BIO CEO & Investor Conference
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Launches Managed Access Program for Lenzilumab
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen to Present at Investor Conferences January 7 and 13, 2022
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Release of Abstracts at ASH
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Humanigen Announces Participation and Presentation at Multiple Conferences in November
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
From Humanigen, Inc.
Via Business Wire
Tickers HGEN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS